Find clinical trials for Pancreatic Cancer in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Rochester, MN, USA:
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Rochester, Minnesota, United States and 15 other locations
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS muta...
Phase 1
Rochester, Minnesota, United States and 22 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Rochester, Minnesota, United States and 21 other locations
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorect ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2....
Phase 1
Rochester, Minnesota, United States and 14 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
Rochester, Minnesota, United States and 71 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 8 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Rochester, Minnesota, United States and 65 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Rochester, Minnesota, United States and 64 other locations
and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors...
Phase 1
Rochester, Minnesota, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal